  
 |
A Strategic Assessment of Infectious Disease Innovations
The objective of this report, issued June 1999, is to identify, critique, and rate emerging infectious disease products available for in-licensing. The analyses are current and discriminating - both the merits and the pitfalls of each product have been stringently reviewed against a number of relevant criteria embracing both product (e.g., mode of action) and company source (e.g., management, pipeline). In the final analysis, readers will be uniquely positioned to act quickly on expanding or launching their infectious disease product line.
Table of Contents
List of Figures and Tables
Preface
Expert Contributors
I. Action Report
II. Executive Summary
III. Introduction
IV. Market Dynamics
V. Report Methodology
Infectious Diseases
VI. Infectious Disease and Chronic Sequelae
VII. Antibiotic Resistance
VIII. Cytomegalo Virus
IX. Fungal Infections
X. Hepatitis B
XI. Hepatitis C
XII. Human Immunodeficiency Virus
XIII. Human Papilloma Virus
XIV. Influenza
XV. Parainfluenza and Respiratory Syncytial Viruses
XVI. Tuberculosis
Platforms
XVII. Immunotherapy (HBV and HCV)
XVIII. Nucleoside Analogs (HBV and HIV)
XIX. Inosine Monophosphate Dehydrogenase (IMPDH) inhibitors (HBV)
XX. Non-Nucleoside Reverse Transcriptase Inhibitors (HIV)
XXI. HIV-1 Fusion Inhibitors (HIV)
XXII. HIV-1 Viral Resistance Assays
XXIII. Nucleoside Analog Reverse Transcriptase Inhibitors (HIV)
XXIV. Human Papilloma Virus Vaccine
XXV. Antimicrobial Peptides
XXVI. Monoclonal Antibody Therapy (CMV)
XXVII. Parainfluenza Virus Vaccine
XXVIII. Antifungal Peptides
XXIX. Conclusion
Infectious Disease Panelists
Joan E. Kapusnik-Uner, Pharm.D.
Senior Knowledge Engineer
First DataBank, Inc.
Theo N. Kirkland III, M.D.
Professor of Pathology and Medicine
Infectious Disease Section
University of California, San Diego
Dimitrios P. Kontoyiannis, M.D.
Assistant Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Leigh Stone
Managing Director/Partner
Ferghana Partners Group
John B. Wright
President
Lifetime Learning, Inc.
Infectious Disease Editorial Board
Joshua Fierer, M.D.
Head, Division of Infectious Diseases
University of California, San Diego
Keith A. Joiner, M.D.
Associate Chairman, Department of Medicine
Director, Investigative Medicine Program
Yale University
William A. Petri, M.D., Ph.D.
Professor of Internal Medicine, Pathology and Microbiology
Division of Infectious Diseases
University of Virginia
For pricing information and instructions on how to order this publication, [click here - link to auto-calculate form].
|
|
